



Poster Programme

Poster Session 1: 18:00-19:00, Sunday 27 October - All odd numbers (P1, P3, P5, P7 etc)
Poster Session 2: 14:30-15:30, Monday 28 October - All even numbers (P2, P4, P6, P8 etc)

Clinical studies and field trials	
[P001]	Antibody responses in serum and nasal mucus induced by the intranasal vaccination with a whole-virion inactivated vaccine of A(H5N1) virus in healthy human individuals A. Ainaï*, E. van Riet, S. Tamura, T. Suzuki, A. Kawaguchi, H. Asanuma, T. Odagiri, M. Tashiro, T. Kurata, H. Hasegawa, <i>National Institute of Infectious Diseases, Japan</i>
[P002]	Use of Microarray technology for the detection of a range of RNA viruses in clinical samples A. Aldabbagh*, W. Irving, P. Tighe, <i>University of Nottingham, UK</i>
[P003]	Immunogenicity and safety of DTP/HB/Hib (Bio Farma) vaccine compared to DTP/HB (Bio Farma) vaccine given simultaneously with Hib (Registered) vaccine in Indonesian infants K. Rusmil ^{1,3} , N.S. Bachtiar ^{*2} , E. Fadlyana ^{1,3} , M. Dhamayanti ^{1,3} , R. Tarigan ^{1,3} , S. Hadyana ^{1,3} , ¹ Padjadjaran University, Indonesia, ² Bio Farma, Indonesia, ³ Hasan Sadikin Hospital, Indonesia
[P004]	Bacille Calmette-Guérin revaccination modulates serum IgE levels in a randomized controlled trial T.S. Peleteiro ¹ , E.L. Conceição ^{*1,2} , E.S. Oliveira ^{1,2} , C.M.C. Mendes ² , F.S.N. Sampaio ² , T. Barbosa ¹ , ¹ Gonçalo Moniz Research Center, Brazil, ² Federal University of Bahia, Brazil
[P005]	BAT-1/TNF polymorphisms in patients with tuberculosis (TB) or tuberculosis and human immunodeficiency virus co-infection (TB-HIV) E.L. Conceição ^{*1,2} , M.S. Rocha ² , C.N. Amoedo ² , F.S. Santos ^{1,2} , A.T. Carletto ² , C.M.C. Mendes ¹ , V.R.R. Mendonça ^{1,2} , J.M. Marinho ^{3,4} , T. Barbosa ² , ¹ Universidade Federal da Bahia, Brazil, ² Centro de Pesquisas Gonçalo Moniz - FIOCRUZ, Brazil, ³ Escola Bahiana de Medicina e Saude Publica, Brazil, ⁴ Hospital Especializado Octavio Mangabeira, Brazil
[P006]	Booster immune response in children of 6-7 years of age, randomly assigned to four intervention groups with two MMR vaccines applied by aerosol or by injection J.L. Diaz-Ortega ^{*1} , J.V. Bennett ² , D. Castañeda-Desales ¹ , D.M. Arellano-Quintanilla ¹ , D. Martínez ³ , M.L. García-García ¹ , L.P. Cruz-Hervert ¹ , E. Ferreira-Guerrero ¹ , J. Fernández de Castro ¹ , ¹ Instituto Nacional de Salud Publica, Mexico, ² Retired from Centers for Disease Control and Prevention, USA, ³ Instituto Nacional de Enfermedades Respiratorias, Mexico
[P007]	Effects of paracetamol on the hepatitis B vaccination response in young adults: Antibody levels and specific T- and B-cells A.M.C.M. Doedée ^{*1} , G.J. Boland ² , N.M. Kannegieter ¹ , K. Öztürk ¹ , A.M. Buisman ¹ , A. de Klerk ¹ , V. Lammers ¹ , H. van Loveren ¹ , R. Janssen ¹ , ¹ National Institute for Public Health and the Environment, The Netherlands, ² University Medical Centre Utrecht, The Netherlands
[P008]	Protective properties of inactivated virosomal influenza vaccine M.K. Erofeeva*, I.J. Nickonorov, V.L. Maksakova, M.A. Stukova, O.S. Konshina, E.A. Okhapkina, E.M. Voitchevskaya, S.A. Korovkin, S.J. Melnikov, O.I. Kiselev, <i>Research Institute of Influenza, Russia</i>
[P009]	Safety, humoral and cell-mediated immune responses to Oka varicella vaccine in subjects with diabetes mellitus A. Hata ^{*1} , F. Inoue ¹ , M. Yamasaki ¹ , J. Fujikawa ¹ , Y. Kawasaki ¹ , Y. Hamamoto ¹ , S. Honjo ¹ , E. Moriishi ¹ , Y. Mori ^{2,3} , H. Koshiyama ¹ , ¹ Kitano Hospital, The Tazuke Kofukai Medical Research Institute, Japan, ² National Institute of Biomedical Innovation, Japan, ³ Kobe University, Japan
[P010]	Contribution of influenza and other respiratory viruses to hospitalization in Valencia, Spain, during the 2012-2013 winter season: A prospective hospital-based active-surveillance study J. Puig-Barberà ^{*1} , X. López-Labrador ^{1,2} , J. Díez-Domingo ¹ , M. Ruíz-García ³ , J. Barrenengoa-Sañudo ⁴ , R. Larrea-González ⁴ , R. Limón-Ramírez ⁵ , M. Tortajada-Girbés ⁶ , C. Carratalà-Munuera ⁷ , V. Gil-Gillén ⁸ , ¹ Centro Superior de Investigación en Salud Pública, Spain, ² Universitat de València, Spain, ³ Centro de Salud Pública de Castellón, Spain, ⁴ Hospital General de Castellón, Spain, ⁵ Hospital La Plana de Vila-real, Spain, ⁶ Hospital Doctor Peset, Spain, ⁷ Hospital San Juan de Alicante, Spain, ⁸ Hospital General de Elda, Spain
[P011]	The "global influenza hospital surveillance network" (gihsn): A step forward J. Puig-Barberà ^{*1} , E. Burtseva ² , A. Sominina ³ , O. Launay ⁴ , M. Ciblak ⁵ , A. Tormos ^{1,6} , C. Mahé ⁶ , ¹ Centro Superior de Investigación en Salud Pública, Spain, ² D.I. Ivanovsky Institute of Virology, Russia, ³ Research Institute of Influenza, Russia, ⁴ Centre d'Investigation Clinique de Vaccinologie Cochin Pasteur, France, ⁵ National Influenza Reference Laboratory, Turkey, ⁶ Sanofi Pasteur, Lyon, France

[P012]	<p>Epidemiological characteristics of hospitalizations associated with circulating seasonal influenza strains: Analysis from the “global influenza hospital surveillance network” (GIHSN) J. Puig-Barberà*¹, A. Tormos^{1,2}, A. Sominina³, O. Launay⁴, M. Ciblak⁵, A. Natividad-Sancho¹, A. Buigues-Vila¹, S. Martínez-Úbeda¹, E. Burtseva⁶, ¹Centro Superior de Investigación en Salud Pública, Spain, ²Sanofi Pasteur, Lyon, France, ³Research Institute of Influenza, Russia, ⁴Centre d’Investigation Clinique de Vaccinologie Cochin Pasteur, France, ⁵National Influenza Reference Laboratory Capp-Istanbul, Turkey, ⁶D.I. Ivanovsky Institute of Virology, Russia</p>
[P013]	<p>Epidemiological analysis from a worldwide network of hospitals - “global influenza hospital surveillance network” (GIHSN) J. Puig-Barberà*¹, A. Tormos^{1,2}, A. Natividad-Sancho¹, A. Buigues-Vila¹, S. Martínez-Úbeda¹, ¹Centro Superior de Investigación en Salud Pública, Spain, ²Sanofi Pasteur, Lyon, France</p>
[P014]	<p>Influence of pre-existing Hemagglutination-inhibition titers against historical influenza strains on antibody response to inactivated trivalent influenza vaccine in adults 50-80 years of age D.M. Carter¹, C.J. Lin¹, M.P. Nowalk¹, M.E. Sundaram¹, T. Friedrich¹, C.E. Bloom¹, R.K. Zimmerman¹, T.M. Ross*¹, ¹Vaccine and Gene Therapy Institute of Florida, USA, ²University of Pittsburgh, USA, ³Marshfield Clinic Research Foundation, USA</p>
[P015]	<p>Paper withdrawn</p>
[P016]	<p>Human papillomavirus oropharynx infection in healthy university students 18 to 25 years of age in Valencia, Spain M. Sastre-Cantón*¹, M.A. Bracho^{1,2}, J. Díez-Domingo¹, S. Pérez-Vilar¹, L. Pérez-Breva¹, S. Alemán-Sánchez¹, J. Puig-Barberà¹, J.J. Vilata-Corell³, ¹CSISP-FISABIO, Spain, ²Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública (CIBERESP), Spain, ³Hospital General Universitario, Spain</p>
[P017]	<p>Antibody response and its durability of cell culture-derived Japanese encephalitis vaccine in Japanese healthy adults K. Takahashi*¹, I. Aoyama¹, T. Yumisashi¹, T. Kase¹, T. Takasaki², ¹Osaka Prefectural Institute of Public Health, Japan, ²National Institute of Infectious Diseases, Japan</p>
[P018]	<p>Safety and immunogenicity of inactivated poliovirus vaccine based on sabin-strains with and without aluminium hydroxide adjuvant: Phase I trial in adults and infants P. Verdijk*¹, N.Y. Rots², M.G.C.T. van Oijen¹, S.M. Oberste³, C.J. Boog¹, H. Okayasu⁴, R.W. Sutter⁴, W.A.M. Bakker¹, ¹Institute for Translational Vaccinology (Intravacc), The Netherlands, ²National Institute for Public Health and the Environment (RIVM), The Netherlands, ³Centers for Disease Control and Prevention, USA, ⁴World Health Organization, Switzerland</p>
[P019]	<p>Cross-protection against lethal pneumococcal pneumonia of mice by immunization of novel pneumococcal surface protein A (PspA) fusions Z. Piao¹, Y. Akeda*¹, D.E. Briles², K. Ubukata³, K.J. Ishii^{1,4}, K. Tomono¹, K. Oishi^{1,5}, ¹Osaka University, Japan, ²University of Alabama at Birmingham, USA, ³Kitasato University, Japan, ⁴National Institute of Biomedical Innovation, Japan, ⁵National Institute of Infectious Diseases, Japan</p>
Human vaccines - infectious diseases (bacterial)	
[P020]	<p>Characterization of glycosylation sites in <i>S. pneumoniae</i> capsular polysaccharide-protein conjugates G.C. Barazzone*¹, V. Pinto², D. Donnarumma², M.M. Tanizaki¹, N. Norais², F. Berti², ¹Instituto Butantan, Brazil, ²Novartis Vaccines and Diagnostics, Italy</p>
[P021]	<p>Paper withdrawn</p>
[P022]	<p>Paper withdrawn</p>
[P023]	<p>Defining a protective epitope on factor H binding protein, a key meningococcal virulence factor and vaccine antigen E.C. Cartocci*, A.F. Faleri, E.M. Malito, <i>Novartis Vaccines & Diagnostics, Italy</i></p>
[P024]	<p>Characterization of CRM 197 conjugated vaccines and their excipients interaction with silicone surface T. Chevolleau*, B. Eyraud, F. Crozet, B. Duroux, F. Gratier, J-B. Hamel, <i>Becton & Dickinson, France</i></p>
[P025]	<p>Vaccine development by using outer membrane vesicles released from a detoxified mutant of enterotoxigenic <i>Escherichia coli</i> S-H. Kim², S-M. Jung¹, S-H. Lee², K.T. Chung¹, Y-H. Kang¹, S-H. Cho*¹, ¹Korea National Institute of Health, Republic of Korea, ²Korea Research Institute of Bioscience and Biotechnology (KRIBB), Republic of Korea</p>
[P026]	<p>Vaccination with <i>Clostridium difficile</i> PSII polysaccharide antigen adjuvanted with KLH induced broad-based enhancement of adaptive immune responses and protection in mice H. Chow*, M. Sagermann, Z. Ma, G. Vandentam, M. Monteiro, <i>Stellar Biotechnologies, USA</i></p>
[P027]	<p>Lack of influence of the <i>IFNG 874T/A</i> polymorphism in the magnitude of the IFN-γ response of healthy volunteers revaccinated with BCG in Salvador, Bahia, Brazil E.L. Conceição*^{1,2}, F.S.N. Sampaio¹, P.A. Schwingel³, E.S. Oliveira^{1,2}, C.M.C. Mendes¹, A. Souza-Machado¹, M.M. Oliveira⁴, J.M. Marinho^{5,6}, M. Barral-Netto², T. Barbosa², ¹Universidade Federal da Bahia, Brazil, ²Centro de Pesquisas Gonçalo Moniz - FIOCRUZ, Brazil, ³Universidade de Pernambuco, Brazil, ⁴Hospital Universitário Clementino Fraga Filho - UFRJ, Brazil, ⁵Escola Bahiana de Medicina e Saúde Pública, Brazil, ⁶Hospital Especializado Octávio Mangabeira, Brazil</p>

[P028]	Selectivity in IgG subclass response to live plague vaccine in humans V.A. Feodorova ^{*1,2} , M.A. Khizhnyakova ^{1,2} , A.M. Lyapina ^{1,3} , M.V. Telepnev ⁴ , O.V. Ulianova ^{1,2} , E.P. Lyapina ³ , V.L. Motin ⁴ , ¹ Saratov State Veterinary Institute, Russia, ² Saratov State Agrarian University, Russia, ³ Saratov State Medical University, Russia, ⁴ University of Texas Medical Branch, USA
[P029]	Immunogenic form of enterobacterial common antigen (ECA) isolated from <i>Shigella sonnei</i> phase II: Structure and application as universal antibacterial vaccine component T.K. Gozdziejewicz ^{*1} , J. Lukaszewicz ¹ , C. Lugowski ^{1,2} , ¹ Polish Academy of Sciences, Poland, ² University of Opole, Poland
[P030]	Sca autotransporter protein of <i>Orientia tsutsugamushi</i>, as novel vaccine target for scrub typhus N.Y. Ha [*] , Y. Kim, M.S. Choi, I.S. Kim, N.H. Cho, <i>Seoul National University College of Medicine, Republic of Korea</i>
[P031]	Recombinant GroEL of <i>S.Typhi</i> co-administered with rIL-22 shows enhanced immunogenicity and protective efficacy against microbial infections in mice G. Kaur [*] , C. devi, C. Nimker, A. Bansal, <i>Defence Institute of Physiology and Allied Sciences, India</i>
[P032]	Glycoconjugate anti-pertussis vaccine S. Koj ^{*1} , T. Niedziela ¹ , C. Lugowski ^{1,2} , ¹ Polish Academy of Sciences, Poland, ² University of Opole, Poland
[P033]	A promising novel formulation of <i>Staphylococcus aureus</i> vaccine protects mice via antibodies and CD4⁺ effector T cells F. Mancini ^{*1,2} , E. Monaci ¹ , S. Tavarini ¹ , S. Rossi-Paccani ¹ , G. Grandi ¹ , E. De Gregorio ¹ , S. Nuti ¹ , F. Bagnoli ¹ , E. Soldaini ¹ , S. Bertholet ¹ , ¹ Novartis Vaccines & Diagnostics, Italy, ² University of Padua, Italy
[P034]	Modification of a novel recombinant glyco-conjugate vaccine improves protection against <i>Francisella tularensis</i> L.E. Marshall ^{*1} , R.M. Thomas ¹ , R.V. D'Elia ¹ , T.R. Laws ¹ , E.D. Williamson ¹ , T.P. Atkins ^{1,3} , J. Cuccui ² , M.G. Moule ² , B.W. Wren ² , J.L. Prior ¹ , ¹ Dstl, UK, ² London School of Hygiene and Tropical Medicine, UK, ³ University of Exeter, UK
[P035]	Age distribution of suspect cholera cases in Africa and its implications for the use of oral cholera vaccine M. Mengel [*] , B. Gessner, <i>Agence de Medicine Preventive, France</i>
[P036]	Harnessing genomic and immunoinformatic approaches to identify immunogenic H. pylori sequences for vaccine development S.F.M. Moss ¹ , S.H.Z. Zhang ¹ , J.A. Aponte ¹ , J.D. Desrosiers ^{1,2} , F.T. Terry ^{1,3} , L.F. Fast ^{1,2} , W.M. Martin ^{1,3} , A.S.D.G. Groot ^{2,3} , L.M. Moise ^{2,3} , P.D. Groot ^{*3} , ¹ Rhode Island Hospital, USA, ² University of Rhode Island, USA, ³ EpiVax Inc, USA
[P037]	Characterization of combinatorial epitope assemblies for optimal expression, solubility and immunogenicity R.L. Liu ¹ , D.G.A. Groot ^{1,2} , L.M. Moise ^{1,2} , P.D. Groot ^{*2} , ¹ University of Rhode Island, USA, ² EpiVax, Inc, USA
[P038]	Advanced T cell epitope-driven vaccine design: A multi-pathogen biodefense vaccine against burkholderia L.R. Liu ¹ , A.M. Ardito ^{1,2} , M.B. Martin ^{1,2} , D.J. Desrosiers ¹ , M.L. Moise ^{1,2} , D.G.A.S. Groot ^{1,2} , P.D. Groot ^{*2} , ¹ University of Rhode Island, USA, ² EpiVax, Inc, USA
[P039]	Paper withdrawn
[P040]	Evaluation of a <i>Burkholderia pseudomallei</i> outer membrane vesicle vaccine in nonhuman primates H. Petersen ¹ , W. Nieves ¹ , K.E. Russell-Lodrigue ^{1,2} , C.J. Roy ^{*1,2} , L.A. Morici ¹ , ¹ Tulane University School of Med., USA, ² Tulane National Primate Research Center, USA
[P041]	Pertinence of a change in the meningococcal C conjugate vaccine schedule in the Region of Valencia, Spain. Mathematical modelling L. Pérez-Breva ¹ , R.J. Villanueva-Micó ² , J. Villanueva-Oller ³ , L. Acedo-Rodríguez ² , F.J. Santonja-Gómez ² , J.A. Moráñon-Fernández ² , R. Abad-Torrealblanca ³ , J.A. Vázquez-Moreno ³ , M. Sastre-Cantón ^{*1} , J. Díez-Domingo ^{1,5} , ¹ Centro Superior Investigación Salud Pública, Valencia, Spain, ² Universidad Politécnica de Valencia, Spain, ³ Universidad Complutense de Madrid, Spain, ⁴ Instituto Salud Carlos III, Spain, ⁵ Universidad Católica "San Vicente Mártir", Spain
[P042]	Nucleotide sequence analysis of factor H binding proteins in invasive meningococcal disease isolates in Ontario and Québec, Canada, 2009-2012 R.S.W. Tsang [*] , F.B. Jamieson, B. Lefebvre, R. Gilca, S. Deeks, P. De Wals, P. Rawte, C. Tremblay, D. Law, J. Zhou, <i>Public Health Agency of Canada, Canada</i>
[P043]	Paper withdrawn
[P044]	Paper withdrawn
[P045]	Safety and immunogenicity of a novel multivalent OspA vaccine against lyme borreliosis in healthy adults: A double-blind, randomised, dose-escalation phase I/II clinical trial N.W. Wressnigg ^{*1} , E.M.P. Pöllabauer ¹ , G.A. Aichinger ¹ , D.P. Portsmouth ¹ , B.C. Crowe ¹ , B.S. Schmitt ² , M.M. Müller ³ , H.K. Kollaritsch ¹ , M.E. Esen ⁴ , P.N.B. Barrett ¹ , ¹ Vaccine R&D Baxter Bioscience, Austria, ² Health Center Mainz, Germany, ³ Medical University Vienna, Austria, ⁴ University of Tübingen Institute of Tropical Medicine, Germany

Human vaccines - infectious diseases (other)	
[P046]	FastVax: Accelerated vaccine design, production and delivery for emerging infectious diseases and biodefense A.S. De Groot* ^{1,2} , L. Einck ¹ , L. Moise ^{1,2} , M. Chambers ³ , R.W. Malone ⁴ , M. Ardito ¹ , W. Martin ¹ , ¹ EpiVax, Inc., USA, ² Institute for Immunology and Informatics, University of Rhode Island, USA, ³ Aldevron, Inc., USA, ⁴ WCCT Global, Inc., USA
[P047]	Vaccines to control and prevent sexually transmitted infections: A way forward N. Broutet ¹ , C. Deal* ² , U. Fruth ¹ , ¹ World Health Organization, Switzerland, ² National Institute of Allergy and Infectious Diseases, USA
[P048]	iVAX web-based vaccine design F. Terry ¹ , J. Tivin ¹ , L. Moise ^{1,2} , W. Martin ¹ , A.S. De Groot ^{1,2} , P.D. Groot* ¹ , ¹ EpiVax, Inc., USA, ² Institute for Immunology and Informatics, University of Rhode Island, USA
[P049]	Correlation of specific T-cell responses using a validated IFNγ ELISPOT and qualified intracellular cytokine staining in clinical trial sample analysis H.J.T. van Zeeburg*, N. Bachmayer, F. Tirion, M. Bosch, E. Wiesken, S. Kostense, J. Hendriks, <i>Crucell, The Netherlands</i>
[P050]	A vaccinia virus A27 protein fused with plasmodium circumsporozoite as a potent malaria vaccine candidate A. Vijayan*, C. Gomez, E. Mejias, M. Esteban, <i>Centro Nacional de Biotecnologia (CNB-CSIC), Spain</i>
Human vaccines - infectious diseases (viral)	
[P051]	Generation of recombinant fowlpox virus 9 (FPV9) carrying simian immunodeficiency virus (SIVmac239) sequences as an HIV vaccine candidate R. Alsafi* ¹ , T. Blanchard ^{1,2} , C.P. Chikkana-Gowda ¹ , P. Valley ¹ , ¹ University of Manchester, UK, ² North Manchester General Hospital, UK
[P052]	Functional activity of vaccine induced antibodies in volunteers after immunization with vaccine contained Leningrad-3 mumps virus strain A.V. Atrasheuskaya*, G.M. Ignatyev, <i>FSUC SIC Microgen, Moscow, Russia</i>
[P053]	Decision making process in a family for HPV vaccination among 9-17 year old children: Does it matter? A. Berenson*, M. Rahman, <i>University of Texas Medical Branch, USA</i>
[P054]	Paper withdrawn
[P055]	Comparative study on immunogenicity among split, intradermal and MF59-adjuvanted influenza vaccines in elderly institutionalized subjects M. Basileo ¹ , A.M. Iorio ² , G. Bartolini ³ , C. Bianchini ⁴ , G. Menculini ⁵ , P. Tozzi ⁶ , B. Camilloni* ² , ¹ Genomic Genetics and Biology Center of Innovation, Italy, ² Univeristy of Perugia, Italy, ³ Opera Pia Bartolomei Castori, Italy, ⁴ Cooperativa Sociale A.I.D.A.S., Italy, ⁵ RP Bittoni, Italy, ⁶ USL 2, Italy
[P056]	Towards a DNA-based live attenuated vaccine against the yellow fever virus K. Dallmeier*, J. Neyts, <i>KULeuven, Belgium</i>
[P057]	Low immunogenicity predicted for hemagglutinin of emerging avian-origin H7N9 influenza A.S. De Groot* ^{1,2} , M. Ardito ¹ , F. Terry ¹ , L. Levitz ¹ , T. Ross ³ , L. Moise ^{1,2} , W. Martin ¹ , ¹ EpiVax, Inc., USA, ² University of Rhode Island, USA, ³ Vaccine and Gene Therapy Institute of Florida, USA
[P058]	Immunogenicity of a new recombinant dengue virus envelope protein in mice H. Fahimi* ¹ , H. Allahyari ² , M. Mohammadipour ¹ , M. Sadeghizadeh ¹ , ¹ Tarbiat Modares University, Iran, ² Tehran University of Medical Sciences, Iran
[P059]	Paper withdrawn
[P060]	Paper withdrawn
[P061]	Immunogenicity and safety of booster doses of inactivated polio vaccine S. Fukushima* ¹ , T. Nakano ² , H. Shimizu ³ , A. Hamada ¹ , ¹ Tokyo Medical University Hospital, Japan, ² Kawasaki Medical University, Japan, ³ National Institute of Infectious Diseases, Japan
[P062]	Adult hospitalizations attributable to influenza and to other respiratory viruses during two influenza season in Quebec, Canada R. Gilca* ^{1,2} , M. Douville-Fradet ^{1,2} , R. Amini ¹ , H. Charest ¹ , J. Dubuque ⁴ , A. Thuot ⁵ , A. Poirier ⁶ , D. Grimard ⁷ , E. Simoneau ⁸ , P. Dolc ⁹ , N. Boulianne ^{1,2} , G. De Serres ¹ , ¹ Institut National de Santé Publique du Québec, Canada, ² CHU de Quebec, Canada, ³ Laval University, Canada, ⁴ Ministère de la santé et des services sociaux du Québec, Canada, ⁵ Saint-Jean-sur-Richelieu, Canada, ⁶ CSSSTR, Canada, ⁷ CSSS de Chicoutimi, Canada, ⁸ Cité de la santé de Laval, Canada, ⁹ CSSS Rimouski-Neigette, Canada
[P063]	Immunogenicity of two doses of Gardasil in preadolescents V. Gilca* ^{1,2} , C. Sauvageau ^{1,2} , N. Boulianne ^{1,2} , G. De Serres ^{1,2} , M. Dionne ^{1,2} , ¹ Quebec Public Health Institute, Canada, ² Laval University, Canada
[P064]	The effect of a challenge dose of Gardasil or Cervarix when administered to girls who previously received two doses of Gardasil V. Gilca* ^{1,2} , C. Sauvageau ^{1,2} , N. Boulianne ^{1,2} , G. De Serres ^{1,2} , M. Dionne ^{1,2} , ¹ Quebec Public Health Institute, Canada, ² Laval University, Canada

[P065]	Epidemiology of hospitalizations related with SRV in children up to 5 year old in Spain (1997-2011) R. Gil-Prieto ^{*1,2} , A. Gonzalez-Escalada ¹ , P. Marín-García ¹ , A. Gil de Miguel ¹ , ¹ Rey Juan Carlos University, Spain, ² Harvard Medical School, USA
[P066]	The seroepidemiology of HAV antibodies in Victoria, Australia A.E. Heywood ^{*1} , A.T. Newall ¹ , Z. Gao ¹ , J. Wood ¹ , A. Breschkin ² , S. Nicholson ² , H.F. Gidding ¹ , D.E. Dwyer ³ , G.E. Gilbert ³ , P.B. McIntyre ⁴ , ¹ University of New South Wales, Australia, ² Victorian Infectious Disease Research Laboratory (VIDRL), Australia, ³ Westmead Hospital, Australia, ⁴ The Children's Hospital at Westmead, Australia
[P067]	Application of standardized method for varicella virus content testing with national standard vaccine J.Y. Hong [*] , D.K. Kim, H.J. Oh, <i>National Institute of Food and Drug Safety Evaluation, Republic of Korea</i>
[P068]	T cells induced upon vaccination with a novel, pan influenza A, peptide-based vaccine in humans can cross-react with diverse influenza A strains C. Horlock [*] , J.N. Francis, C.J. Bunce, B. Georges, <i>Immune Targeting Systems (ITS) Ltd., UK</i>
[P069]	This paper will be presented in poster session 2 Comparative effectiveness of high- versus standard-dose influenza vaccines among US residents aged 65 years and older: Preliminary results H.S. Izurieta ^{*1} , N. Thadani ² , Y. Lu ¹ , R. Franks ² , T. MaCurdy ² , D. Pratt ¹ , A. Maurer ² , C. Worrall ³ , H. Hong ² , J. Kelman ³ , ¹ Food and Drug Administration, USA, ² ACUMEN, USA, ³ Centers for Medicare & Medicaid Services (CMS), USA
[P070]	Paper withdrawn
[P071]	Protection against influenza and rabies virus infection using innovative RActive® technology B. Petsch ¹ , M. Schnee ¹ , A.B. Vogel ² , E. Jasny ^{*1} , D. Voss ¹ , K.J. Kallen ¹ , L. Stitz ² , T. Kramps ¹ , ¹ CureVac GmbH, Germany, ² Friedrich-Loeffler-Institut, Germany
[P072]	Diversity of Human Rotavirus circulating among children under 5 years of age after the introduction of rotavirus vaccine in South Korea H-S. Jeong ^{*1} , J.W. Lee ^{1,2} , H. Lee ¹ , S.W. Lee ¹ , ¹ KNIH, KCDC, Republic of Korea, ² Chungbuk National University, Republic of Korea
[P073]	DNA vaccine encoding Hantavirus Gn, targeted to the MHC class II compartment by LAMP, significantly elicits specific immune responses and induces immune protection against Hantavirus challenge in vivo D.B. Jiang [*] , Y.J. Sun, L.F. Cheng, K. Yang, <i>The Fourth Military Medical University, China</i>
[P074]	Paper withdrawn
[P075]	Live attenuated influenza vaccine based on a cold-adapted influenza B virus strain does not induce serum antibodies but provides protective efficacy in mice O.S. Kashirina [*] , Y.M. Vasiliev, <i>Mechnikov Research Institute of Vaccines and Sera, Russia</i>
[P076]	Paper withdrawn
[P077]	Use of the mini-pig as an animal model of human Norovirus GII.4 Sydney variant J.W. Kim ^{*1,2} , H.S. Jeong ¹ , S.W. Lee ¹ , ¹ National Institute of Health, Republic of Korea, ² Chungbuk National University, Republic of Korea
[P078]	Mucosal vaccination with recombinant adenovirus encoding nucleoprotein provides potent protection against influenza virus infection J.Y. Kim ^{*1} , S.H. Kim ¹ , Y. Choi ² , H.H. Nguyen ² , M.K. Song ² , J. Chang ¹ , ¹ Ewha Womans University, Republic of Korea, ² International Vaccine Institute, Republic of Korea
[P079]	The molecular epidemiology of circulating rotaviruses : 5-year surveillance in the region of Gwangju, South Korea: 2008-2012 S.H. Kim ^{*1} , M.J. Kim ¹ , H-S. Jeong ² , H-Y. Kee ¹ , S. Lee ¹ , S.K. Kim ¹ , D.R. Ha ¹ , E-S. Kim ¹ , J.K. Chung ¹ , ¹ Health & Environment Institute of Gwangju, Republic of Korea, ² Korea Center for Disease Control and Prevention, Republic of Korea
[P080]	Progress towards measles elimination after introduction of supplementary immunization in Japan K. Komase [*] , M. Takeda, <i>National Institute of Infectious Diseases, Japan</i>
[P081]	Evaluation of protective potential of antibody response to influenza A virus fusion peptide and M2 protein ectodomain F. Kostolansky, Z. Stanekova [*] , J. Janulikova, T. Mikuskova, V. Mucha, E. Vareckova, <i>Institute of Virology, Slovakia</i>
[P082]	A virus-like particle vaccine for Enterovirus 71 utilising a recombinant modified vaccinia Ankara as expression system K.B. Lauer ^{*1} , C.P. Chikkanna-Gowda ¹ , P.J. Valley ¹ , R. Borrow ^{1,2} , T.J. Blanchard ^{1,3} , ¹ University of Manchester, UK, ² Public Health England, UK, ³ North Manchester General Hospital, UK
[P083]	Quasi-species and distribution of mixed bases in varicella-zoster virus vaccine and clinical strains J.I. Kim ¹ , G.Y. Ji ¹ , S.J. Kim ² , E.M. Kim ² , S.H. Ha ² , C.H. Lee ^{*1} , ¹ Chungbuk National University, Republic of Korea, ² Mogam Biotechnology Research Institute, Republic of Korea
[P084]	A formalin-inactivated EV71 vaccine candidate development in Taiwan C.C. Liu [*] , H.Y. Lin, M.S. Guo, J.Y. Chang, A.H. Chou, Y.H. Chow, P. Chong, <i>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Taiwan</i>
[P085]	Paper withdrawn

[P086]	Adjuvant effect of toll-like receptors agonists in genetic immunization with pA27L against smallpox O. Martinez* ¹ , M. Ramirez ^{1,2} , T. Sanchez ¹ , C. Rivera ¹ , L. Vazquez ¹ , E. Miranda ¹ , E. Rios ² , M. Otero ¹ , ¹ University of Puerto Rico, Puerto Rico, ² Universidad Central del Caribe, Puerto Rico
[P087]	Broadly reactive influenza H1N1 CD4+ t-cell epitopes identified by immunoinformatic methods L. Moise ^{1,2} , H. Latimer ¹ , R. Tassone ¹ , M. Ardito ¹ , F. Terry ¹ , C. Boyle ¹ , W. Martin ¹ , A.S. De Groot ^{1,2} , P.D. Groot* ¹ , ¹ EpiVax, Inc., USA, ² University of Rhode Island, USA
[P088]	Lot-to-lot consistency of live attenuated SA 14-14-2 Japanese encephalitis vaccine manufactured in a Good Manufacturing Practices facility and non-inferiority with respect to an earlier product K. Zaman ¹ , A.M. Naser* ¹ , M. Power ² , M. Yaich ² , L. Zhang ³ , A.S. Ginsburg ² , S.P. Luby ^{1,4} , M. Bhardwaj ⁵ , J. Flores ² , ¹ International Centre for Diarrhoeal Disease Research, Bangladesh, ² Program for Appropriate Technology in Health, USA, ³ Chengdu Institute of Biological Products, Co., Ltd., China, ⁴ Stanford University, USA, ⁵ GVK Biosciences Private Limited, India
[P089]	Higher antibody titres in response to MF59®-adjuvanted seasonal influenza vaccine compared with non-adjuvanted vaccines in children under six years of age T. Nolan* ¹ , L.C. Bravo ² , A. Ceballos ³ , E. Mitha ⁴ , G. Gray ⁵ , B. Quiambao ⁶ , S. Patel ⁷ , H. Bock ⁷ , N. Nazaire-Bernal ⁷ , E. Forleo ⁷ , ¹ University of Melbourne & Murdoch Childrens Research Institute, Australia, ² University of the Philippines Manila - Philippine General Hospital, The Philippines, ³ Instituto Médico Rio Cuarto, Argentina, ⁴ Newtown Clinical Research Centre, South Africa, ⁵ Chris Hani Baragwanath Hospital, Johannesburg, South Africa, ⁶ Research Institute for Tropical Medicine, The Philippines, ⁷ Novartis Vaccines and Diagnostics, USA
[P090]	Expression of major viral proteins of HAV and HEV for combined vaccine approach Y. Oh*, J.M. Kim, C.H. Kweon, E.J. Kim, E.J. Choi, J.Y. Song, QIA, Republic of Korea
[P091]	Paper withdrawn
[P092]	A purified inactivated Crimean-Congo hemorrhagic fever virus vaccine derived from Vero cells A. Ozdarendeli* ¹ , E. Berber ¹ , N. Canakoglu ¹ , M. Ertek ¹ , S. Tonbak ¹ , I. Sozdutmaz ¹ , M. Aktas ¹ , A. Kalkan ¹ , ¹ Erciyes University, Turkey, ² Firat University, Turkey, ³ Erciyes University, Turkey, ⁴ Institute of Refik Saydam, Turkey, ⁵ Firat University, Turkey, ⁶ Erciyes University, Turkey, ⁷ Firat University, Turkey, ⁸ Karadeniz Technical University, Turkey
[P093]	Controlling vaccine wastage with smaller vials: A cost-minimization model for Bangladesh, Mozambique, India (Uttar Pradesh), and Uganda W. Yang ¹ , M. Parisi* ² , B.J. Lahue ² , D.M. Bishai ¹ , ¹ Johns Hopkins University, USA, ² Becton, Dickinson and Company, USA
[P094]	Paper withdrawn
[P095]	Influenza vaccine effectiveness, by age group and strain, in preventing laboratory confirmed influenza admissions in adults 18 years old or older targeted for influenza vaccination, during the 2012-13 influenza season: A test-negative study J. Puig-Barberà* ¹ , X. López-Labrador ^{1,4} , J. Díez-Domingo ¹ , M. Ruíz-García ² , J. Barrenengoa-Sañudo ³ , R. Larrea-González ³ , R. Limón-Ramírez ⁵ , M. Tortajada-Girbés ⁶ , C. Carratalà-Munuera ¹ , V. Gil-Gillén ⁸ , ¹ Centro Superior de Investigación en Salud Pública, Spain, ² Centro de Salud Pública de Castellón, Spain, ³ Hospital General de Castellón, Spain, ⁴ Universitat de València, Spain, ⁵ Hospital La Plana de Vila-real, Spain, ⁶ Hospital Doctor Peset, Spain, ⁷ Hospital San Juan de Alicante, Spain, ⁸ Hospital General de Elda, Spain
[P096]	The global influenza hospital surveillance network (GIHSN): Assessment of statistical heterogeneity between study sites J. Puig-Barberà* ¹ , A. Natividad-Sancho ¹ , A. Sominina ³ , O. Launay ² , M. Ciblak ⁴ , A. Tormos ^{1,5} , A. Buigues-Vila ¹ , S. Martínez-Úbeda ¹ , E. Burtseva ⁶ , ¹ Centro Superior de Investigación en Salud Pública, Spain, ² Centre d'Investigation Clinique de Vaccinologie Cochin Pasteur, France, ³ Research Institute of Influenza, Russia, ⁴ National Influenza Reference Laboratory Capp-Istanbul, Turkey, ⁵ Sanofi Pasteur, Lyon, France, ⁶ D.I. Ivanovsky Institute of Virology, Russia
[P097]	Immunological role of L3L gene in DNA vaccination against smallpox M. Ramirez* ¹ , O. Martinez ¹ , T. Sanchez ¹ , C. Rivera ¹ , L. Vazquez ¹ , E. Miranda ^{1,2} , E. Rios-Olivares ¹ , M. Otero ¹ , ¹ University of Puerto Rico, Puerto Rico, ² Universidad Central del Caribe, Puerto Rico
[P098]	An IRES-containing Venezuelan equine encephalitis virus vaccine is immunogenic and protects cynomolgus macaques from aerosol challenge S.L. Rossi ¹ , E. Wang ¹ , G. Leal ¹ , S.Z. Killeen ² , H. Vinet-Oliphant ² , M.J. Kuroda ² , K.E. Russell-Lodrigue ² , N.A. Bergren ¹ , S.C. Weaver ¹ , C.J. Roy* ^{2,3} , ¹ University of Texas Medical Branch, USA, ² Tulane National Primate Research Center, USA, ³ Tulane School of Medicine, USA
[P099]	Review of the seasonality of influenza in selected countries in tropical Asia and Africa M.J. Sanicas* ¹ , E. Forleo ² , G. Pozzi ¹ , ¹ Universita degli Studi di Siena, Italy, ² Novartis Vaccines & Diagnostics, Italy
[P100]	The burden of tick-borne encephalitis in Slovenia R. Šmit, University of Ljubljana, Slovenia
[P101]	Cost-effectiveness of tick-borne encephalitis vaccination in Slovenia R. Šmit, University of Ljubljana, Slovenia

[P102]	Impact of the quaternary structure of human secretory-IgA on viral neutralization activity in upper respiratory tract T. Suzuki*, A. Kawaguchi, A. Ainai, S. Tamura, R. Ito, M. Tashiro, H. Hasegawa, <i>National Institute of Infectious Diseases, Japan</i>
[P103]	Enhanced protection in C57BL/6 mice immunized with a serum-free Vero cell-derived Japanese encephalitis vaccine combined with Advax™ delta inulin adjuvant is associated with increased virus-stimulated splenocyte IL-17 and IFN-γ production H. Toriniwa* ¹ , M. Lobigs ² , N. Petrovsky ³ , T. Komiya ¹ , ¹ <i>Kitasato Daiichi Sankyo Vaccine co., LTD, Japan</i> , ² <i>University of Queensland, Australia</i> , ³ <i>Flinders Medical Centre/Flinders University and Vaxine Pty Ltd, Australia</i>
[P104]	Flu vaccination acceptance among children and awareness of mothers in Japan Y. Tsuchiya*, K. Machida, <i>Waseda University, Japan</i>
[P105]	High specific activity of the vaccine preparation comprising recombinant protein with 4 copies of the influenza virus M2e L.M. Tsybalova* ¹ , L.A. Stepanova ¹ , V. Kupriyanov ² , M.V. Potapchuk ¹ , A.V. Korotkov ¹ , N.V. Ravin ² , ¹ <i>Institute of Influenza, Russia</i> , ² <i>Centre Bioengineering, Russia</i>
[P106]	Estimating influenza vaccine effectiveness among healthcare workers in an university hospital and comparison with hospitalized patients (2004-2009) Y. Baghdadi ¹ , S. Amour* ² , N. Voirin ² , C. Regis ¹ , B. Comte ² , B. Kim ² , B. Coppéré ² , B. Lina ³ , P. Vanhems ^{1,2} , ¹ <i>Université Claude Bernard Lyon 1, France</i> , ² <i>Hôpital Edouard Herriot, France</i> , ³ <i>Groupement Hospitalier Est, France</i>
[P107]	Perception of A/H1N1 influenza and acceptance of pandemic influenza vaccine among university staff S. Amour*, K. Djehiche, A. Zamora, A. Bergeret, P. Vanhems, <i>Université Claude Bernard Lyon 1, France</i>
[P108]	HA2 glycopolyptide of influenza A haemagglutinin as a potential vaccine immunogen E. Vareckova* ¹ , Z. Stanekova ¹ , J. Janulikova ¹ , I. Adkins ² , M. Kosova ² , V. Mucha ¹ , P. Sebo ² , F. Kostolansky ¹ , ¹ <i>Institute of Virology, Slovakia</i> , ² <i>Institute of Microbiology of the ASCR, Czech Republic</i>
[P109]	The HEV 239 Vaccine constitutes a promising vaccine candidate to manage animal sources of human HEV infection P. Liu, L. Wang*, Y-L. Wei, <i>Peking University, China</i>
[P110]	Designs of HA antigen play a key role in determining the protective antibody responses against H7 subtype influenza viruses L. Zhang ¹ , S. Wang* ^{1,3} , N. Jia ² , W. Cao ² , Z. Huang ¹ , S. Lu ^{1,3} , ¹ <i>The First Affiliated Hospital of Nanjing Medical University, China</i> , ² <i>Beijing Institute of Microbiology and Epidemiology, China</i> , ³ <i>University of Massachusetts Medical School, USA</i>
[P111]	Do occupational physicians vaccinate enough? S. Wicker* ¹ , C. Betsch ¹ , ¹ <i>University Hospital Frankfurt, Germany</i> , ² <i>University Erfurt, Germany</i>
[P112]	Novel influenza vaccine based on recombinant <i>Bacillus subtilis</i> spore G.Y. Zhao*, S.H. Sun, Y. Guo, Z.H. Kou, H. Yu, Y.S. Zhou, <i>State Key Laboratory of Pathogen and Biosecurity, China</i>
Human vaccines - non-infectious diseases	
[P113]	A vaccine approach against pathologic TAR DNA binding protein-43 (TDP-43): Investigating its efficacy in vitro and in transgenic animal models of amyotrophic lateral sclerosis (ALS) P.Y. Lin* ^{1,2} , J. Rudra ^{1,2} , C.S. Umbaugh ^{1,3} , O.T. Folorunso ^{1,3} , A. Barrett ^{1,2} , A.P. Pierce ^{1,2} , ¹ <i>The University of Texas Medical Branch, USA</i> , ² <i>Sealy Center for Vaccine Development, USA</i> , ³ <i>Cynthia Woods Mitchell Center for Neurodegenerative Diseases, USA</i>
[P114]	Paper now [O2.7]
Immunology / animal models	
[P115]	Innate immune response innate immune response in mice vaccinated with trypanosoma rangeli and infected trypanosoma cruzi B. Basso* ^{1,2} , V. Marini ¹ , ¹ <i>National University of Córdoba, Argentina</i> , ² <i>National Service of Chagas' Disease, Argentina</i> , ³ <i>Catholic University of Córdoba, Argentina</i>
[P116]	Efficacy of Flu SAM (HA) vaccine against Influenza infection in mice and ferrets M. Brazzoli* ¹ , S. Buccato ¹ , D. Magini ¹ , A. Bonci ¹ , D. Casini ¹ , S. Mangiavacchi ¹ , P. Fontani ¹ , D. Maione ¹ , A.J. Geall ² , S. Bertholet ¹ , ¹ <i>Novartis Vaccines & Diagnostic, Italy</i> , ² <i>Novartis Vaccines & Diagnostic, USA</i>
[P117]	Aluminium hydroxide significantly enhances Th1 and Th2 immune responses in mice to a subvirion influenza vaccine and confers superior protection T. Zheng, B.M. Buddle*, A. Heiser, <i>AgResearch Limited, New Zealand</i>
[P118]	Substitution K73,78,85R in the PB1-F2 protein of the influenza A virus enhances humoral response and confer increased prophylactic effect in vivo I.K. Košík*, M.P. Práznovská, I.K. Krejnová, G.R. Russ, <i>Slovak Academy of Science, Slovakia</i>
[P119]	Enhancement of CD4+ and CD8+ T-Cell population through Th-1 response in Balb/C Mice vaccinated with chimera DNA vaccine against tuberculosis and leishmania co-infection M. Kumar* ¹ , P. Shankar ¹ , S. Kumar ² , S. Tousif ² , A. Singh ² , S. Singh ¹ , ¹ <i>All India Institute of Medical Sciences, India</i> , ² <i>International Centre for Genetic Engineering and Biotechnology, India</i>

[P120]	Broad protective immunity against widely divergent influenza subtypes induced by fusion protein 4sM2 in BALB/c mice J-S. Lee*, M-Y. Chowdhury, C-J. Kim, <i>Chungnam National University, Republic of Korea</i>
[P121]	Modulation of gene responses in peripheral blood mononuclear cells from EV71-infected rhesus neonates is correlated to viral pathogenesis Q.H. Li*, Y. Zhang, E.X. Yang, <i>Chinese Academy of Medicine Science & Peking Union Medical College, China</i>
[P122]	Advantages of low dose influenza virus challenge in the ferret model A.C. Marriott*, B.K. Dove, T.J.H. Bean, K.A. Ryan, C.J. Whittaker, B. Hallis, N.J. Silman, M.W. Carroll, <i>Public Health England, UK</i>
[P123]	Antibodies and complement are essential for protection against a pneumococcal lethal challenge in mice elicited by a nasal vaccine composed of PspA C.S. Rivillas, E.N. Miyaji, P.L. Ho, M.L.S. Oliveira*, <i>Instituto Butantan, Brazil</i>
[P124]	Assessment of the experimental model of tuberculosis in goats for use in vaccine trials B. Pérez de Val* ¹ , E. Vidal ¹ , M. Nofrarias ¹ , S. López-Soria ¹ , P.J. Cardona ² , M. Domingo ¹ , ¹ <i>Centre de Recerca en Sanitat Animal (CRESA), Spain</i> , ² <i>Fundació Institut per a la Investigació en Ciències de la Salut Germans Trias i Pujol, Spain</i>
[P125]	Development of type 1 diabetic urinary tract infection murine models for vaccine candidate testing J.L. Enderle, A.L. Miller, B. Elsom, J. Patel, R.B. Pyles*, <i>University of Texas Medical Branch, USA</i>
[P126]	The development of a novel humanized MHC (HLA-A11/DR1) transgenic mouse model S.H. Sun* ¹ , Y. Zeng ¹ , G.Y. Zhao ¹ , T.T. Gao ¹ , C.F. Liu ¹ , Y.C. Lone ² , Y.S. Zhou ¹ , ¹ <i>State Key Laboratory of Pathogen and Biosecurity, China</i> , ² <i>Université Paris-Sud, France</i>
[P127]	Development of a murine infection model for Dengue virus type 4 V. Vasquez*, E. Infante, L. Li, G.A. Campbell, R. Pyles, G.N. Milligan, N. Bourne, A.D.T. Barrett, <i>University of Texas Medical Branch, USA</i>
[P128]	The use of Sphingosine1-phosphate receptor (S1PR) modulators as a novel approach to improve vaccine immunization E. Cirelli, V. Gesa, A. Riccomi, S. Vendetti*, <i>Istituto Superiore di Sanità, Italy</i>
Production / manufacturing	
[P129]	Stabilization of a model flu vaccine by collapse freeze drying C. Anamur*, G. Winter, J. Engert, <i>Ludwig Maximilians University, Germany</i>
[P130]	Continuous influenza virus production in cell culture shows a periodic accumulation of defective interfering particles T. Frensing* ¹ , F.S. Heldt ¹ , I. Behrendt ¹ , I. Jordan ² , D. Flockerzi ¹ , Y. Genzel ¹ , U. Reichl ^{1,3} , ¹ <i>Max Planck Institute for Dynamics of Complex Technical Systems, Germany</i> , ² <i>ProBioGen AG, Germany</i> , ³ <i>Otto-von-Guericke-University, Germany</i>
[P131]	Scale-up of a cell based influenza virus production process using ReadyToProcesSTM equipment J. Tschöp, A. Magnusson, M. Lundgren*, C. Kaisermayer, <i>GE Healthcare Bio-Sciences AB, Sweden</i>
Regulatory / societal / economic / programmatic / legislation subjects	
[P132]	Potential market size for TSOL18 vaccine against porcine cysticercosis in western and central Africa E.A. Assana*, S.G. Gumbi, M.D. Donadeu, <i>University of Ngaoundéré, Cameroon</i>
[P133]	Sustainability and self financing of immunization programs in 12 sub Saharan Africa countries: Current situation and innovative perspectives A. Colombini ¹ , J.B. Le Gargasson* ¹ , M. Drach ² , ¹ <i>AMP, France</i> , ² <i>University of Paris Dauphine, France</i>
[P134]	Anthropological study on optimal approaches for the use of DTP-HepB-Hib vaccines in Uniject in Senegal and Vietnam E. Guillermet* ¹ , F. Hane ² , M. Le Thi Phong ³ , T. Nguyen Thi Thi ³ , L. Nguyen Thi Phuong ³ , T. Phan Dang ³ , D. Tran Van ³ , H.M. Dicko ¹ , B. Gessner ¹ , A. Colombini ¹ , ¹ <i>Agence de Médecine Préventive, France</i> , ² <i>Université de Ziguinshor, Senegal</i> , ³ <i>National Institute of Hygiene and Epidemiology, Viet Nam</i>
[P135]	Literature review of anthropological studies on diarrhea in the DRC in anticipation of a potential rotavirus vaccine introduction E. Guillermet*, A. Colombini, B. Gessner, G. Breugelmanns, <i>AMP, France</i>
[P136]	Being a "good" woman despite of cervical cancer or genital warts: The psychosocial and economic burden of HPV infection, in Kenya E. Guillermet* ¹ , J. Siso ² , I. Nyamongo ² , K.T.H. Oanh ³ , B.D. Gessner ¹ , C. Perrey ⁴ , P. Amiel ⁴ , A. Colombini ¹ , ¹ <i>Agence de Médecine Préventive, France</i> , ² <i>University of Nairobi, Kenya</i> , ³ <i>Center for Supporting Community Development Initiative, Viet Nam</i> , ⁴ <i>Center for Supporting Community DeInstitut de Cancérologie, Gustave Roussy., France</i>
[P137]	Paper withdrawn
[P138]	Population impact of Australia's national varicella immunisation program on varicella and herpes zoster A.E. Heywood* ¹ , H. Wang ² , K.K. Macartney ^{2,3} , P.B. McIntyre ^{2,3} , ¹ <i>University of New South Wales, Australia</i> , ² <i>National Centre for Immunisation Research and Surveillance (NCIRS), Australia</i> , ³ <i>University of Sydney, Australia</i>

[P139]	Costs and financing of routine immunization and new vaccine introduction in Ghana J-B. Le Gargasson ^{*1} , F. Nyongator ² , M. Adibo ³ , B. Gessner ¹ , A. Colombini ¹ , ¹ Agence de Médecine Préventive, France, ² Ministry of Health Ghana, Ghana, ³ Independent Consultant, Ghana
[P140]	Socio-economic traits and their influence on vaccine rates N. Moreno-Millán [*] , A. Mas-Casals, P. Robles-Raya, E. de Frutos, A. Sánchez-Callejas, S. Gómez-Roig, J. Botanes, N. Aresté, L. Morató, <i>Vaccine Group of the Catalan Society of Family Medicine, Spain</i>
[P141]	Awareness of cervical cancer and human papillomavirus (HPV) and acceptability of the HPV vaccine in Morocco M. Mouallif ^{*1,3} , H. Bowyer ² , S. Festali ¹ , A. Albert ³ , Y. Filali ⁴ , S. Guenin ³ , P. Delvenne ³ , J. Waller ² , M. Ennaji ¹ , ¹ University Hassan II mohammedia, Morocco, ² University College of London, UK, ³ University of Liège, Belgium, ⁴ University My Ismail, Morocco
[P142]	Paper withdrawn
[P143]	Policies and procedures around staff influenza vaccination in Australian public hospitals H. Seale [*] , C.R. MacIntyre, <i>University of New South Wales, Australia</i>
[P144]	Examining the views of key stakeholders regarding the provision of occupational influenza vaccination for healthcare workers in Australia H. Seale [*] , L.C. Lim, <i>University of New South Wales, Australia</i>
[P145]	Paper withdrawn
[P146]	Journey to vaccination: A qualitative exploration of explicit and implicit factors underpinning adult vaccination behavior A. Wheelock ^{*1} , A. Parand ¹ , B. Rigole ² , A. Thomson ² , M. Miraldo ¹ , C. Vincent ¹ , N. Sevdalis ¹ , ¹ Imperial College London, UK, ² Sanofi Pasteur, France
Vaccine safety	
[P147]	Association of the use of MMRV in infants by pediatric infectious disease specialists with that of other affiliated providers B.K. Ackerson [*] , L.S. Sy, T.C. Cheetham, S.J. Jacobsen, <i>Kaiser Permanente Southern California Department of Research and Evaluation, USA</i>
[P148]	Reported adverse events following influenza immunization in people over 60 years of age. Valencian Community (Spain). Seasons 2010-11, 2011-12 and 2012-13 A.M. Alguacil-Ramos [*] , A. Portero-Alonso, R. Martin-Ivorra, E. Pastor-Villalba, J.A. Lluch-Rodrigo, <i>Dirección General de Salud Pública. Conselleria de Sanitat. Valencia, Spain</i>
[P149]	Validation of the French national health insurance information system as a tool in vaccine safety assessment: Application to febrile convulsions after pediatric measles/mumps/rubella immunization M. Hanf ^{1,2} , C. Quantin ^{3,4} , C.P. Farrington ⁵ , E. Benzenine ³ , N.M. Hocine ⁶ , M. Velten ^{7,8} , P. Tubert-Bitter ^{1,2} , S. Escolano ^{*1,2} , ¹ INSERM U1018, France, ² University Paris Sud, France, ³ Teaching Hospital of Dijon, France, ⁴ INSERM U866, France, ⁵ The Open University, UK, ⁶ Conservatoire National des Arts et Métiers, France, ⁷ University of Strasbourg, France, ⁸ Paul Strauss Comprehensive Cancer Center, France
[P150]	Assessment of vaccine approach using safe irradiated toxins as potent immunogens L. Boussag-Abib ¹ , F. Rebbouh ¹ , M-F Martin-Eauclaire ² , F. Laraba-Djebari ^{*1} , ¹ USTHB, Algeria, ² Université de la Méditerranée, France
[P151]	Observational post-authorisation safety study to describe the safety profile of the diphtheria, tetanus and acellular pertussis vaccine (trixaxis®) as a 5th dose in 4-6 year old spanish children J.G.S. Garcia-Sicilia ^{*1} , F.G. Gimenez ² , C.L. Lambermont ³ , L.M. Marcelon ³ , N.Q. Qizilbash ⁴ , F.W. Weber ⁵ , ¹ Hospital Universitario La Paz, Spain, ² Hospital Torrecárdenas, Spain, ³ Sanofi Pasteur MSD, France, ⁴ OXON Epidemiology, Spain, ⁵ Sanofi Pasteur, France
[P152]	Risk of immune thrombocytopenic purpura after vaccination in adults S.K. Sandhu ¹ , M.F. Daley ² , A. Akhtar ¹ , R. Ball ¹ , C. Ross ³ , S.T. O'Leary ^{2,3} , J.M. Glanz ³ , R. Baxter ⁴ , M. Rett ⁵ , H.S. Izurieta ^{*1} , ¹ Food and Drug Administration (FDA), USA, ² University of Colorado, USA, ³ Kaiser Permanente Colorado, USA, ⁴ Kaiser Permanente Vaccine Study Center, USA, ⁵ Harvard Pilgrim Health Care Institute and Harvard Medical School, USA
[P153]	Exploring the risk factors for vaccine-associated and non-vaccine associated febrile convulsions in a large pediatric cohort S.Y. Tartof, H-F. Tseng, A.L. Liu, L. Qian, L.S. Sy, R.C. Hechter, S.M. Marcy, S.J. Jacobsen [*] , <i>Kaiser Permanente Southern California, USA</i>
[P154]	Rotavirus vaccine surveillance in the Valencian community, Spain: Sensitivity of the passive surveillance system to report intussusception following vaccination S. Pérez-Vilar ^{*1} , J. Puig-Barberà ¹ , J. Gomar-Fayos ² , E. Pastor-Villalba ³ , J. Díez-Domingo ¹ , ¹ Centro Superior de Investigación en Salud Pública, CSISP-FISABIO, Spain, ² Dirección General de Farmacia y Productos Sanitarios, Spain, ³ Dirección General de Salud Pública, Spain

[P155]	Intussusception hospitalizations in infants before and after introduction of rotavirus vaccines in the Valencian Community: Implications for post-licensure monitoring of vaccine safety using electronic healthcare databases in Spain S. Pérez-Vilar*, J. Puig-Barberà, S. Martínez-Úbeda, A. Natividad-Sancho, A. Rodríguez-Galán, J. Díez-Domingo, <i>Centro Superior de Investigación en Salud Pública, CSISP-FISABIO, Spain</i>
[P156]	Intussusception risk following rotavirus vaccination in the Valencian community, Spain S. Pérez-Vilar*, S.A. Romio ^{2,3} , R. Gil-Prieto ⁴ , H.S. Izurieta ⁵ , J. Puig-Barberà ¹ , J. Díez-Domingo ¹ , ¹ <i>Centro Superior de Investigación en Salud Pública, CSISP-FISABIO, Spain</i> , ² <i>Erasmus University Medical Center, The Netherlands</i> , ³ <i>University Milano-Bicocca, Italy</i> , ⁴ <i>Rey Juan Carlos University, Spain</i> , ⁵ <i>Food and Drug Administration, USA</i>
Vectors / adjuvants / drug delivery	
[P157]	A combination of new insertion loci and endogenous promoters drives higher transgene immunogenicity in MVA N.K. Alharbi ^{1,2} , M.G. Cottingham ¹ , S.C. Gilbert ¹ , ¹ <i>University of Oxford, UK</i> , ² <i>King Abdullah International Medical Research Center, Saudi Arabia</i>
[P158]	Immunization with recombinant semliki forest virus induces cellular immune response against rabies virus glycoprotein R.M. Astray*, D.C. Ventini, A.L.P. Puglia, V.L.L. Boldorini, F.G. Silva, C.A. Pereira, <i>Instituto Butantan, Brazil</i>
[P159]	A simple cationic nanoliposome as a vaccine delivery system for soluble leishmania antigens (SLA): Preparation, characterization and immune response evaluation A. Badiee*, M.R. Jaafari ¹ , A. Khamesipour ² , ¹ <i>Mashhad University of Medical Sciences, Iran</i> , ² <i>Tehran University of Medical Sciences, Iran</i>
[P160]	Chitosan combined with immunopotentiators as vaccine adjuvants: Are there any advantages? O. Borges*, F. Lebre, D. Bento, <i>University of Coimbra, Portugal</i>
[P161]	Inactivated seasonal influenza vaccines with adjuvants: Direct comparison of immunogenicity in mice M.I. Chernikova*, O.S. Kashirina, Y.M. Vasiliev, <i>Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia</i>
[P162]	Polysaccharide-dsrna based nanoparticles as adjuvant systems for a hpv peptide antigen J.F. Correia-Pinto*, N. Csaba ¹ , M.J. Alonso ¹ , J.T. Schiller ² , ¹ <i>University of Santiago de Compostela, Spain</i> , ² <i>National Cancer Institute, USA</i>
[P163]	New vaccinia virus promoter as candidate for future vaccines M. Di Pilato*, E. Mejías-Perez, C.E. Gómez, B. Perdiguero, C.O. Sorzano, M. Esteban, <i>Centro Nacional De Biotecnología, Spain</i>
[P164]	Characterization of candidate vaccine adjuvants improving immune responses in aged and newborn mice T. Ebensen*, K. Schulze, S. Weissmann, D. Lirussi, C.A. Guzmán, <i>Helmholtz Centre for Infection Research (HZI), Germany</i>
[P165]	Modified vaccinia lister (MVL), a safe and easy to produce vector for human or veterinary vaccines A. Ferrier-Rembert*, J. Dimier ¹ , A.L. Favier ¹ , D. Spehner ² , R. Drillien ² , J.M. Crance ¹ , C.N. Peyrefitte ¹ , ¹ <i>Institu de Recherche Biomédicale des Armées, France</i> , ² <i>Institut de génétique, Biologie Moléculaire et Cellulaire, France</i>
[P166]	Targeted delivery of antigen loaded hydroxyethyl starch nanocapsules to human dendritic cells enhances antigen-specific cellular immune responses M. Fichter*, M. Dedters ¹ , A. Pietrzak-Nguyen ¹ , L. Pretsch ¹ , C. Meyer ¹ , A. Doganci ¹ , J. Birkholz ¹ , K. Landfester ² , G. Baier ² , S. Gehring ¹ , ¹ <i>Pediatric Immunology - Children's Hospital Mainz, Germany</i> , ² <i>Max Planck Institute for Polymer Research, Germany</i>
[P167]	A new concept of DNA vaccine adjuvant using the VHSV regions involved in triggering a type I IFN response A. Martinez-Lopez ¹ , P. Garcia-Valtanen*, M. Ortega-Villaizan ¹ , V. Chico ¹ , S. Imad Cheikh ¹ , J. Coll ² , A. Estepa ¹ , ¹ <i>Instituto de Biología Molecular y Celular, Elche, Spain</i> , ² <i>Instituto de Investigaciones Agrarias (INIA), Madrid, Spain</i>
[P168]	IFN-λ1 (IL-29) gene serves as an immunologic adjuvant to modulate local and systemic immune responses of HCV core expressing DNA vaccine C. Hartoonian*, M. Mahdavi ² , A. Arashkia ² , P. Amir Kalvanagh ² , M. Ebtekar ² , Z. Sepehrizadeh ¹ , K. Azadmanesh ² , ¹ <i>Tehran University of Medical Sciences, Iran</i> , ² <i>Pasteur Institute of Iran, Iran</i>
[P169]	Development and assessment of non-native virus-like particles with enhanced immunogenicity M. Hyakumura*, W-S. Cheong, S. Flegeltaub, H.J. Netter, <i>Monash University, Australia</i>
[P170]	Development of archetypal virus like particles decorated with functional antibody domains N.J. Kingston*, I. Caminschi ² , M. Lahoud ² , W-S. Cheong ¹ , H.J. Netter ¹ , ¹ <i>Monash University, Australia</i> , ² <i>Burnet Institute, Australia</i>
[P171]	Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus J-S. Lee*, M-Y. Chowdhury, C-J. Kim, <i>College of Veterinary Medicine, Republic of Korea</i>

[P172]	Potent mucosal immunization with surface-displayed CTA1-fused sM2 protein on <i>Lactobacillus casei</i> induces protection against highly pathogenic influenza A virus J-S. Lee*, M-Y. Chowdhury, C-J. Kim, <i>Chungnam National University, Republic of Korea</i>
[P173]	Protective efficacy and safety of a pandemic influenza virus split vaccine adjuvanted with a deacyl lipooligosaccharide-based adjuvant in mice N.G. Lee* ¹ , J.I. Ryu ¹ , S.A. Park ¹ , J.A. Choi ² , M.K. Song ² , K.S. Kim ³ , J.W. Jang ³ , Y.J. Cho ³ , ¹ <i>Sejong University, Republic of Korea</i> , ² <i>International Vaccine Institute, Republic of Korea</i> , ³ <i>EyeGene, Republic of Korea</i>
[P174]	Characterization of the structure and biological activity of a vaccine adjuvant, de-O-acylated lipooligosaccharide N.G. Lee* ¹ , J.E. Han ¹ , Y.J. Cho ¹ , ¹ <i>Sejong University, Republic of Korea</i> , ² <i>EyeGene, Republic of Korea</i>
[P175]	Immunomodulation produced by a polysaccharide on humoral response of bovines immunized with glycoprotein d of bohv5 expressed in <i>Pichia pastoris</i> I.L. Araujo, L.A. Dummer, A.G. Dos Santos Junior, M.C. Da Rosa, R.E.A. Piraine, F.P.L. Leite*, <i>Federal University of Pelotas, Brazil</i>
[P176]	Vaccine refrigerator regulator with data logger and back-up power supply P.J. McColloster* ¹ , A.A. Martin-de-Nicolas ^{1,2} , C. Vallbona ¹ , ¹ <i>Baylor College of Medicine, USA</i> , ² <i>Rice University, USA</i>
[P177]	Deletion of antibody-encoded tolerogenic signals to improve a dendritic cell-targeted vaccine delivery platform D. Aguirre ¹ , B. Martin ¹ , L.P. Cousens ² , W.D. Martin ² , A.S. De Groot ^{1,2} , L. Moise* ^{1,2} , P.D. Groot* ² , ¹ <i>University of Rhode Island, USA</i> , ² <i>EpiVax, Inc., USA</i>
[P178]	Stability and immunogenicity of vaccines in dissolvable microneedle patches E. Allen, O. Flynn, C. O'Mahony, A.M. Crean, A.C. Moore*, <i>University College Cork, Ireland</i>
[P179]	Controlled delivery of antigens and adjuvants through PRINT nanoparticles S.N. Mueller* ¹ , S.M. Tian ¹ , A. Pandya ¹ , J.M. DeSimone ^{1,2} , ¹ <i>University of North Carolina at Chapel Hill, USA</i> , ² <i>North Carolina State University, USA</i>
[P180]	Virus-like particles as a scaffold for HIV-1 antigenic sequences M. Hyakumura ¹ , N. Bitto ¹ , W-S. Cheong ¹ , P. Poubourios ² , H.J. Netter* ¹ , ¹ <i>Monash University, Australia</i> , ² <i>Burnet Institute, Australia</i>
[P181]	Paper withdrawn
[P182]	Candidate particulate antigen delivery system based on <i>Quillaja brasiliensis</i> saponins L. Quirici* ¹ , S.G. Verza ² , M. Mastrogiovanni ¹ , I. Miraballes ¹ , G. Casanova ¹ , G. Gosmann ² , G.G. Ortega ² , F.A. Ferreira ¹ , ¹ <i>Universidad de la República, Uruguay</i> , ² <i>Universidade Federal do Rio Grande do Sul, Brazil</i>
[P183]	Flagellin enhances tumor-specific CD8⁺ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model T.C. Ngyen ^{1,2} , S.H. Hong ^{1,2} , J.I. Sin ³ , H.V.D. Vu ^{1,2} , K. Jeong ^{1,2} , K.O. Cho ^{1,2} , S. Uematsu ⁴ , S. Akira ⁵ , S.E. Lee ^{1,2} , J.H. Rhee* ^{1,2} , ¹ <i>Clinical Vaccine R&D Center, Republic of Korea</i> , ² <i>Chonnam National University, Republic of Korea</i> , ³ <i>Kangwon National University, Republic of Korea</i> , ⁴ <i>The University of Tokyo, Japan</i> , ⁵ <i>Osaka University, Japan</i>
[P184]	Influenza viral hemagglutinin-targeted macrocyclic peptides as an antiviral agent M. Saito* ¹ , M. Ozawa ² , F. Yasui ¹ , T. Sasaki ³ , T. Munakata ¹ , Y. Tobita ¹ , R. Itoh ⁴ , K. Munekata ¹ , K. Tsukiyama-Kohara ² , A. Sakurai ¹ , ¹ <i>Tokyo Metropolitan Institute of Medical Science, Japan</i> , ² <i>Kagoshima University, Japan</i> , ³ <i>PeptiDream Inc., Japan</i> , ⁴ <i>The University of Tokyo, Japan</i> , ⁵ <i>Hokkaido University, Japan</i>
[P185]	Vaxonella[®] : a novel <i>Salmonella</i>-based platform for oral delivery of vaccines P. Salerno*, A. Soulier, T. Fjällman, R.M. Cranenburgh, <i>Prokarium Ltd, UK</i>
[P186]	M65 & M101 replication-competent vaccinia viruses as vaccine candidates against leishmaniasis L. Sánchez-Sampedro*, C.E. Gómez, E. Mejías-Pérez, E. Pérez-Jiménez, J.C. Oliveros, and M. Esteban <i>Centro Nacional de Biotecnología, Spain</i>
[P187]	A novel tool for induction of specific T-cell immune responses: complexes of streptavidin fused antigens with biotinylated antibodies targeting receptors on dendritic cell surface O. Stanek* ^{1,2} , L. Majlessi ^{3,4} , I. Linhartova ¹ , L. Parolova ¹ , P. Jinoch ⁵ , F. Skrob ⁵ , C. Leclerc ^{3,4} , P. Sebo ¹ , ¹ <i>Institute of Microbiology AS CR, Czech Republic</i> , ² <i>ICT Prague, Czech Republic</i> , ³ <i>Unité de Régulation Immunitaire et Vaccinologie, France</i> , ⁴ <i>Institut National de la Santé et de la Recherche Médicale, France</i> , ⁵ <i>EXBIO Praha, Czech Republic</i>
[P188]	Mucosal immunization with replication-deficient influenza vector expressing two mycobacterium antigens enhances protective effect of BCG vaccination in mice M.A. Stukova* ¹ , A.R. Sansyrbay ² , B.M. Khairullin ² , A.P.S. Shurigina ¹ , A.V. Fadeev ¹ , E.N. Volgin ² , M. Kassenov ² , O.I. Kiselev ¹ , ¹ <i>Research Institute of Influenza, Russia</i> , ² <i>Research Institute for Biological Safety Problems, Kazakhstan</i>

[P189]	MF59-induced ATP-signaling pathway is not impaired by immunosenescence thereby contributing to an efficient adjuvant activity in the elderly M. Taccone ¹ , M. Gallotta* ¹ , M. Tortoli ¹ , M. Vono ^{1,3} , A. Bonci ¹ , D. Casini ¹ , S. Bertholet ¹ , E. De Gregorio ¹ , D. OHagan ² , A. Seubert ¹ , ¹ Novartis Vaccines and Diagnostics, Italy, ² Novartis Vaccines and Diagnostics, USA, ³ Università di Padova, Italy
[P190]	Adjuvants for influenza vaccines: Comparative studies in mice Y.M. Vasiliev*, O.S. Kashirina, <i>Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia</i>
[P191]	Adjuvanticity evaluation of uniform-sized PLA/PLGA/PELA microparticles in vitro and PLA as adjuvant of H5N1 influenza split vaccine for improvement immune responses L. Wang*, Y. Liu, W. Zhang, T. Yang, G. Ma, <i>Chinese Academy of Sciences, China</i>
[P192]	Biomimetic vaccine formulation for effective antigen presentation and immune activation W. Wei*, D.Z. Ni, H. Yue, G.H. Ma, <i>Chinese Academy of Sciences, China</i>
[P193]	Exploration of micro-sized graphene oxide as "One but All" tumor vaccine delivery system H. Yue* ¹ , W. Wei ¹ , D.Z. Ni ¹ , W.W. Zhang ² , N.N. Luo ¹ , Z.G. Su ¹ , G.H. Ma ¹ , ¹ Chinese Academy of Sciences, China, ² Dalian University, China
[P194]	Design of a new nanoparticulate platform to deliver tumor associated antigens E. Zupancic* ^{1,2} , J. Silva ¹ , M. Videira ¹ , J.N. Moreira ² , H. Florindo ¹ , ¹ University of Lisbon, Portugal, ² University of Coimbra, Portugal
Veterinary vaccines	
[P195]	Paper withdrawn
[P196]	Cross-protective immunity induced by recombinant modified vaccinia Ankara (MVA) virus expressing African horse sickness virus (AHSV) VP2 and VP7 L. Bailey*, N. Manning, P.P.C. Mertens, J. Castillo-Olivares, <i>The Pirbright Institute, UK</i>
[P197]	Safety testing of veterinary vaccines in pigs using magnetic resonance imaging M. Bernau* ¹ , P.V. Kremer ^{1,2} , L.S. Kreuzer ¹ , E. Pappenberger ¹ , K. Cussler ³ , A. Hoffmann ³ , A.M. Scholz ¹ , ¹ Ludwig-Maximilians-University Munich, Germany, ² University of Applied Sciences Weihenstephan-Triesdorf, Germany, ³ Paul-Ehrlich-Institut, Germany
[P198]	Tetraspanin-3 regulates protective immunity against <i>Eimeria</i> infection E. del Cacho* ¹ , M. Gallego ¹ , E.P. Lillehoj ³ , J. Quilez ¹ , A. Ramo ¹ , H.S. Lillehoj ² , ¹ University of Zaragoza., Spain, ² U.S. Department of Agriculture, USA, ³ University of Maryland School of Medicine., USA
[P199]	Protective immunity against avian coccidiosis using antigen-loaded dendritic cells or exosomes E. del Cacho* ¹ , M. Gallego ¹ , E.P. Lillehoj ³ , J. Quilez ¹ , A. Ramo ¹ , H.S. Lillehoj ² , ¹ University of Zaragoza, Spain, ² U.S. Department of Agriculture, USA, ³ University of Maryland School of Medicine, USA
[P200]	The use of RT-PCR for determination of separate endpoints for the strains IB H120 and IB D274 in titration of a live freeze-dried combination vaccine against infectious bronchitis in chickens H.J. Geerligts* ¹ , C.A.M. Meinders ² , W. Duijves ² , J. Zijp-Snel ² , ¹ Zoetis, Belgium, ² PGM Weesp, The Netherlands
[P201]	Development of technological processes and quality control of vaccines for veterinary use M. Hrdá*, P. Kačer, K. Syslová, <i>Institute of Chemical Technology Prague, Czech Republic</i>
[P202]	Protective efficacy of the virus-like particle for canine influenza virus (H3N2) in dogs H-Y. Jeoung, S-I. Lim, J-Y. Song, D-J. An, Y-Y. Jo, Y. Oh*, <i>Animal and Plant Quarantine Agency, Republic of Korea</i>
[P203]	Development of adjuvant composition for viral haemorrhagic septicaemia virus vaccine in flatfish, olive flounder S.J. Jung*, T.N. Vinay, J.W. Ryu, M.J. Oh, <i>Chonnam National University, Republic of Korea</i>
[P204]	Paper withdrawn
[P205]	Evaluating inflammatory reactions after vaccination in piglets by magnetic resonance imaging L.S. Kreuzer* ¹ , M. Bernau ¹ , P.V. Kremer ^{1,2} , E. Pappenberger ¹ , A.M. Scholz ¹ , ¹ Ludwig-Maximilians-University Munich, Germany, ² University of Applied Sciences Weihenstephan-Triesdorf, Germany
[P206]	Seroprevalences induced by foot-and-mouth disease trivalent vaccine in South Korea H.S. Lee*, Y.J. Ko, M.G. Seo, D. Tark, B. Kim, <i>Animal Plant Quarantine Agency, Republic of Korea</i>
[P207]	Bovine immune response against recombinant bovine herpesvirus 5 glycoprotein d I.L. Araujo, L.A. Dummer, A.G. dos Santos Junior, M.C. da Rosa, L.E. Budziarek, F.P.L. Leite*, <i>Federal University of Pelotas, Brazil</i>
[P208]	Immunoprophelaxis strategy for nodavirus prevention in grouper (<i>Epinephelus</i> spp.) larvae C.C. Lin, H.L. Yang, J.H.Y. Lin*, <i>Institute of biotechnology, National Cheng Kung University, Taiwan</i>
[P209]	Salmonella as a vaccine vector for influenza virus Y.C. Lin*, T.T.H. Van, P.J. Coloe, P.M. Smooker, <i>RMIT University, Australia</i>
[P210]	Serological cross reactivity of modified vaccinia ankara recombinant vaccines expressing African horse sickness virus outer capsid protein VP2 N.M. Manning*, K. Bachanek-Bankowska, P.P.C. Mertens, J. Castillo-Olivares, <i>Pirbright Institute, UK</i>
[P211]	A systematic, functional genomics approach for the identification of protective antigens from the cattle tick, <i>Rhipicephalus (Boophilus) microplus</i> C. Maritz-Olivier., <i>University of Pretoria, South Africa</i>

[P212]	Immunoinformatics approach to design influenza genome-derived T cell epitope-based vaccines for swine A.H. Gutierrez ¹ , C. Loving ² , A. Vincent ² , L. Moise ^{1,3} , W. Golde ⁴ , F. Terry ³ , W. Martin ³ , A.S. De Groot ^{1,3} , P.D. Groot ^{*3} , ¹ University of Rhode Island, USA, ² Virus and Prion Diseases Research Unit, NADC, USDA ARS, USA, ³ EpiVax, Inc., USA, ⁴ Plum Island Animal Disease Center, ARS, USDA, USA
[P213]	Swine immunity and protection with experimental foot-and-mouth disease vaccine, O-South East Asia type J-N. Park ¹ , J-H. Park ^{*1} , J-Q. Chu ² , S-Y. Lee ¹ , Y-J. Lee ¹ , R-H. Kim ¹ , K-N. Lee ¹ , S-M. Kim ¹ , D-S. Tark ¹ , H-S. Lee ¹ , ¹ Animal and Plant Quarantine Agency, Republic of Korea, ² bClinical Research Center of the Affiliated Hospital of Guangdong Medical College, China
[P214]	Paper withdrawn
[P215]	Elaboration and verification of high pathogenicity avian influenza vaccine H7N3 used in Jalisco México G.M.A. Robles, J.B. Delgadillo, C. Hinojosa, J. Ramirez*, <i>National Center of Diagnostic Services in Animal Health, Mexico</i>
[P216]	Vaccination with West Nile virus (WNV) recombinant envelope protein E protects red-legged partridges (<i>Alectoris rufa</i>) against viral infection E. Escribano-Romero ¹ , V. Gamino ² , T. Merino-Ramos ¹ , A.B. Blázquez ¹ , M.A. Martín-Acebes ¹ , N. Jiménez de Oya ¹ , A.V. Gutiérrez-Guzmán ² , U. Höfle ² , J.C. Saiz ^{*1} , ¹ INIA, Spain, ² SaBio-IREC, Spain
[P217]	Cytokine and antibody responses in horses showing different clinical forms of African horse sickness virus (AHSV) A. Sánchez-Matamoros ^{*1} , D. Kukielka ¹ , J.M. Sánchez-Vizcaíno ¹ , ¹ Complutense University of Madrid, Spain, ² CEI Campus Moncloa, UCM-UPM, Spain
[P218]	Paper withdrawn
[P219]	Serological responses after immunization of horses with a recombinant adenovirus type 2 (CAV-2) rabies vaccine R.G. Plesca ¹ , B.I. Olaeriu ¹ , I.I. Macovei ¹ , B. Klonjowski ² , G. Savuta ^{*1} , ¹ USAMV Iasi, Romania, ² UMR 1161 Virologie, ANSES INRA ENVA, Maisons-Alfort, France
[P220]	Hypervaccination as prompt non-immune protection V.A. Sergeev, O.V. Sergeyev*, <i>D.Ivanovski Institute of virology, Russia</i>
[P221]	Immunogenicity elicited by dendrimeric peptide constructions against FMDV: Influence of epitope multiplicity and conjugation chemistry E. Blanco ¹ , N. Moreno ¹ , B.G. De la Torre ² , J. Bárcena ¹ , D. Andreu ² , F. Sobrino ^{*1} , ¹ INIA, Spain, ² Universidad Pompeu Fabra, Spain, ³ Centro de Biología Molecular, Spain
[P222]	Vaccine development for Prescottella equi T. Vanniasinkam ^{*1} , C. Giles ² , S. Ndi ² , M. Barton ² , ¹ Charles Sturt University, Australia, ² University of South Australia, Australia
[P223]	Construction of a gene bank of immunologically relevant proteins of African swine fever virus Krasnodar 2012 isolate A.A. Varentsova ^{*1} , I.R. Imatdinov ¹ , N.N. Vlasova ¹ , ¹ Federal Governmental Budgetary Institution Federal Centre for Animal, Russia, ² State Research Institution National Research Institute for Veterinary Virology and Microbiology of the Russian Academy for Agricultural Sciences, Russia
[P224]	Set up of pseudotype-based inhibition assay for the detection of functional antibodies to Influenza virus neuraminidase M. Prevato ^{*1} , A. Nandi ³ , A. Lilja ³ , F. Giusti ¹ , I. Ferlenghi ² , E. Montomoli ¹ , F. Legay ² , A. Bonci ² , ¹ University of Siena, Italy, ² Novartis, Italy, ³ Novartis, USA
[P225]	The co-delivery of esx multivalent TB DNA vaccines with electroporation induces potent immune responses D.O. Villarreal*, D.B. Weiner, <i>University of Pennsylvania, USA</i>
[P226]	HIV-1 Env DNA Vaccine Plus Protein Boost Delivered By EP Expands B- And T-Cell Responses And Neutralizing Phenotype in vivo K. Muthumani ¹ , K. Broderick ² , N. Hutnick ¹ , M. Wise ¹ , J. Yan ² , J. Mendoza ² , C. Tingey ¹ , S. Flingai ¹ , N. Sardesai ² , D. Weiner ^{*1} , ¹ University of Pennsylvania School of Medicine, USA, ² Inovio Pharmaceuticals Inc, USA
[P227]	The Supporting Independent Immunization and Vaccine Advisory Committees (SIVAC) Initiative: progress, lessons learned and priorities for the future A. Adjagba ^{*3} , J. Chaccour ² , R. Biellik ² , K. Senouci ¹ , P. Duclos ¹ , B. Gessner ³ , ¹ World Health Organization IVB, Switzerland, ² Independant Consultant, Switzerland, ³ Agence de Médecine Préventive, France